Quick Answer
CalciMedica, Inc. reported Operating Income Loss of -$23.12 million for the year ending 2025.
- CalciMedica, Inc. showed an increase of +4.5% in Operating Income Loss from 2024 to 2025.
- This data is from CalciMedica, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$10.37 million | Q1 2020: -$7.80 million | Q2 2020: -$6.04 million | Q3 2020: -$6.82 million | Q1 2021: -$11.49 million | Q2 2021: -$7.74 million | Q3 2021: -$8.02 million | Q1 2022: -$4.21 million | Q2 2022: -$3.59 million | Q3 2022: -$3.29 million | Q1 2023: -$22.34 million | Q2 2023: -$6.58 million | Q3 2023: -$4.83 million | Q1 2024: -$5.77 million | Q2 2024: -$6.53 million | Q3 2024: -$5.74 million | Q1 2025: -$6.50 million | Q2 2025: -$6.62 million | Q3 2025: -$5.62 million.
- Over the full 7 years of available data (2019 to 2025), CalciMedica, Inc.'s Operating Income Loss has grown by 38.3%.
- Historical annual values: Fiscal year 2025: -$23.12 million | Fiscal year 2024: -$24.20 million | Fiscal year 2023: -$38.08 million | Fiscal year 2022: -$14.19 million | Fiscal year 2021: -$35.95 million | Fiscal year 2020: -$29.83 million | Fiscal year 2019: -$37.50 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: